TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23802706
Drug: morphine 12 mg
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine 12 mg
Study: 23802706
Drug: oxycodone 8 mg
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxycodone 8 mg
Study: 20226390
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (mean dose, 528 IU/d)
Study: 20226390
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D plus calcium therapy (from Women's Health Initiative Randomized Trial)
Study: 19138241
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (100 mg, single dose)
Study: 24382963
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) therapy
Study: 10843168
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) therapy after placebo
Study: 7702136
Drug: Diamorphine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 3 mg in bolus with bupivacaine 10 ml of 0.25% followed by infusion of bupivacaine 0.1% at 10 ml.h‐1
Study: 7702136
Drug: Diamorphine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 3 mg in infusion with bupivacaine 10 ml of 0.25% followed by infusion of bupivacaine 0.1% at 10 ml.h‐1
Study: 678393
Drug: Amitriptyline 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 6.25 mg
Study: 678393
Drug: Amitriptyline 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 12.5 mg
Study: 678393
Drug: Nortriptyline 25
Normalized name: nortriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline 25 mg
Study: 678393
Drug: Protriptyline 10
Normalized name: protriptyline 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protriptyline 10 mg
Study: 678393
Drug: BW247 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW247 12.5 mg
Study: 678393
Drug: BW247 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW247 25 mg
Study: 31475493
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medication (Mannitol Injection 125 mL every 8 hours, Oxiracetam Injection 4 g once a day)
Study: 31475493
Drug: Medication (Mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Mannitol Injection 125 mL every 8 hours, Oxiracetam Injection 4 g once a day)
Study: 26152604
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose dabigatran (110mg bid)
Study: 18580126
Drug: Physical methods
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical methods of antipyresis (e.g., cooling blankets)
Study: 12680909
Drug: Motilin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motilin infusion (8 pmol (kg min)(-1) for 5 min)
Study: 12680909
Drug: Motilin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motilin infusion following an antral phase III
Study: 8421029
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of cephamandole at the time of tourniquet deflation
Study: 3534590
Drug: Full-dose sequential
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose sequential non-cross-resistant combinations
Study: 26845175
Drug: Trabectedin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin (1.2 mg/m2 administered over 24 h on day 1 of a 21-d treatment cycle)
Study: 24020826
Drug: Preservative-free timolol
Normalized name: Preservative-Free timolol 5 MG/ML Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free timolol gel
Study: 12860778
Drug: Sertraline hydrochloride,
Normalized name: Sertraline Hydrochloride, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline hydrochloride, mean dosage of 95 mg/d
Study: 10668525
Drug: Leflunomide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (20 mg/day after a loading dose of 100 mg/day for 3 days)
Study: 10668525
Drug: Methotrexate (7.5‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (7.5‐15 mg/week)
Study: 6426992
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate 100 mg orally
Study: 19388819
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dapivirine from intravaginal ring (IVR)
Study: 19388819
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dapivirine from intravaginal ring (IVR)
Study: 19388819
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dapivirine from IVR
Study: 19388819
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dapivirine from IVR
Study: 19388819
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg and 25 mg dapivirine from IVR
Study: 17465499
Drug: Parameters influencing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parameters influencing fibrosis and treatment response
Study: 15633894
Drug: Cetirizine hydrochloride
Normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine hydrochloride (10 mg by mouth daily for 1 week)
Study: 11444086
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg daily) + Vitamin C (500 mg)
Study: 7999527
Drug: MgSO4 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 (20 mg/kg over 10 min, followed by 10 mg/kg/h)
Study: 7999527
Drug: MgSO4 and
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MgSO4 and Saline infusion
Study: 3141642
Drug: Fybogel (Ispaghula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fybogel (Ispaghula husk), one sachet twice daily
Study: 28777771
Drug: Family-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based cognitive-behavioral therapy delivered through the Internet
Study: 25197005
Drug: Albuterol and
Normalized name: Albuterol and cromolyn only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol and ipratropium (combined therapy)
Study: 25197005
Drug: Dual bronchodilator
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual bronchodilator therapy (albuterol and ipratropium)
Study: 25197005
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (pre-dose values)
Study: 24557960
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with amoxicillin and lansoprazole for the first 5 days and clarithromycin, ornidazole and lansoprazole for another 5 days.
Study: 24557960
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy with amoxicillin, clarithromycin, and lansoprazole for 14 days.
Study: 8396534
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of MK-0679
Study: 3750367
Drug: Ready-to-use solution
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use solution
Study: 29377592
Drug: Dairy protein
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy protein supplementation (20 g d-1)
Study: 18809153
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg/day
Study: 22531237
Drug: DTaP-IPV-Hep B-PRP-T
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-Hep B-PRP-T vaccine (group 1)
Study: 22531237
Drug: Licensed DTwP-Hep
Normalized name: heparin sodium, porcine Injectable Solution [Hep-Pak]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed DTwP-Hep B//Hib and oral poliovirus vaccines (group 2)
Study: 20447541
Drug: Elevated H‐FABP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated H‐FABP levels (> or =6 ng/ml)
Study: 20447541
Drug: Low H‐FABP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low H‐FABP levels (<6 ng/ml)
Study: 20447541
Drug: H‐FABP levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: H‐FABP levels (median 11.2 ng/ml)
Study: 11997276
Drug: Adjunctive PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive PCI of open (TFG 2/3) arteries
Study: 2367159
Drug: Intramuscular gamma-globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gamma-globulin treatment
Study: 28730418
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg IV low dose cosyntropin test
Study: 28730418
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg IM medium dose cosyntropin test
Study: 28730418
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg IM standard dose cosyntropin test (30 min)
Study: 28730418
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg IM standard dose cosyntropin test (60 min)
Study: 31529070
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test
Study: 18751690
Drug: Nevirapine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine (200 mg twice daily) with rifampicin-based tuberculosis therapy
Study: 18751690
Drug: Nevirapine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine (200 mg twice daily) without rifampicin-based tuberculosis therapy
Study: 10496303
Drug: Oral valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valganciclovir 450, 875, 1750 and 2625 mg once daily for 3 days
Study: 10496303
Drug: Oral valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valganciclovir 900 mg/day
Study: 8768808
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine with 3,700 micrograms histamine/l
Study: 8768808
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine with 200 micrograms histamine/l
Study: 2015149
Drug: lignocaine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 0.1 mg kg‐1
Study: 2015149
Drug: lignocaine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 0.2 mg kg‐1
Study: 2015149
Drug: lignocaine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 0.4 mg kg‐1
Study: 6258871
Drug: APE (adriamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: APE (adriamycin 35 mg/m2 IV D1 Q 3 weeks; procarbazine 60 mg/m2 PO D1-10 Q 3 weeks; VP16-213 130 mg/m2 IV D8, 15 Q 3 weeks)
Study: 6258871
Drug: MOCC (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOCC (methotrexate 15 mg/m2 IV or PO twice weekly D8-21 Q 3 weeks; Oncovin 1.5 mg/m2 IV D8, 15 Q 3 weeks; cyclophosphamide 600 mg/m2 IV D1 Q 3 weeks; CCNU 60 mg/m2 PO Q 6 weeks)
Study: 25930049
Drug: Primary care-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care-based treatment visit
Study: 24460645
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily for 10 ± 4 days then placebo up to day 35
Study: 22832965
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) for 15 weeks
Study: 19299767
Drug: Arndt wire‐guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arndt wire‐guided bronchial blocker (BB)
Study: 19299767
Drug: Cohen Flexi‐tip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohen Flexi‐tip bronchial blocker (BB)
Study: 19299767
Drug: Fuji Uni‐blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuji Uni‐blocker (BB)
Study: 9690731
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg daily for 7 days
Study: 9690731
Drug: Theophylline 250
Normalized name: theophylline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 250 mg on days 1, 2, 4 and 6
Study: 277678
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% sodium fluoride
Study: 277678
Drug: Combined strontium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined strontium and fluoride treatment
Study: 31163551
Drug: Adrenalin saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenalin saline local injection (5 ml, concentration 1:200,000)
Study: 25271172
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) metronidazole, 15 mg/kg
Study: 16952493
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg 3 times daily)
Study: 14973303
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (2.5 microg/kg)
Study: 3565116
Drug: Advised in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advised in advance of the biological test
Study: 3565116
Drug: Live explanation
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live explanation and demonstration of the biological testing procedure
Study: 12145792
Drug: Combination endoscopic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination endoscopic therapy (with epinephrine injection, shaving down the clot with cold guillotining, and bipolar coagulation on the underlying stigmata)
Study: 9651664
Drug: celiprolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol (beta 1‐ and beta 2‐adrenoceptor partial agonist)
Study: 9651664
Drug: propranolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (beta 1‐ and beta 2‐adrenoceptor antagonist)
Study: 9651664
Drug: atenolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (beta 1‐adrenoceptor antagonist)
Study: 2646846
Drug: Cimetidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (600 mg p.o. + 200 mg i.m.)
Study: 2646846
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg p.o. + 50 mg i.m.)
Study: 28318636
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (no treatment)
Study: 15002083
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 500 mg twice daily for 2 weeks
Study: 11708573
Drug: Policosanol 5
Normalized name: policosanol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 5 mg/day for 8 weeks
Study: 11708573
Drug: Policosanol 10
Normalized name: policosanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 10 mg/day for the next 8 weeks
Study: 9144826
Drug: Interventions for
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventions for preventing aggression including a protocol for talking to patients, discussing treatment goals, explaining locked door policies, providing staff meeting schedules, and clarifying appointment procedures.
Study: 3309074
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg) administered 30 min before amphotericin B
Study: 30663869
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg baricitinib
Study: 30663869
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg baricitinib
Study: 30663869
Drug: All-bari-RA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: All-bari-RA (all doses)
Study: 27846612
Drug: High-dose plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose plerixafor (480 μg/kg)
Study: 27846612
Drug: Conventional-dose plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose plerixafor (240 μg/kg)
Study: 25272318
Drug: PRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP plus 2 ranibizumab injections
Study: 21446219
Drug: Oral anti-oxidant
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-oxidant treatment (vitamin C-100 mg BD and vitamin E-400 IU BD) for 45 days
Study: 15373936
Drug: Fumarate tablet
Normalized name: Ferrous Fumarate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumarate tablet (120 mg dimethylfumarate and 95 mg calcium‐monoethylfumarate) taken in the fasted state
Study: 15373936
Drug: Fumarate tablet
Normalized name: Ferrous Fumarate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumarate tablet taken after a standardized breakfast
Study: 11419825
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg every day or 325 mg every 3 days)
Study: 9173339
Drug: Oral estrogen-progestin
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen-progestin contraception
Study: 8282457
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives for > 10 years
Study: 26545392
Drug: Gait training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gait training combined with compelled weight-shift therapy (experimental group, n=14)
Study: 20456839
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine treatment plus Western medicine (group A)
Study: 20456839
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine plus placebo (group B)
Study: 11846968
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (5 mg (kg body mass)(‐1))
Study: 9569951
Drug: HDF 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDF 100 ml/min
Study: 3289929
Drug: Iopamidol 150
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopamidol 150 mg I/ml
Study: 3289929
Drug: Iopamidol 200
Normalized name: iopamidol 200 mg iodine/mL (41 %) INJECTION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol 200 mg I/ml
Study: 29580594
Drug: 10‐mL ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mL ice popsicle
Study: 29580594
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of water at room temperature
Study: 25130571
Drug: HM-derived cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM-derived cream supplement
Study: 15015273
Drug: Tianzhi Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianzhi Granule (TZK) 0.5 g/bag, taken one bag three times a day for two courses of one month each
Study: 8739664
Drug: Mirtazapine, 15‐45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine, 15‐45 mg/day
Study: 8739664
Drug: Amitriptyline, 30‐90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline, 30‐90 mg/day
Study: 1884876
Drug: Bromhexine 72
Normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine 72 mg daily for one month
Study: 22540851
Drug: Pulse radiofrequency
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse radiofrequency treatment at 42°C for 120 seconds to the dorsal root ganglion
Study: 14970281
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with autologous tumor cells genetically modified with an adenoviral vector (Ad‐GM) to secrete GM‐CSF; Intradermal injections every 2 weeks for a total of three to six vaccinations
Study: 8836336
Drug: Mizolastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (10 mg once daily)
Study: 7930305
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg once daily)
Study: 7410896
Drug: A/New Jersey
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/New Jersey subvirion vaccine
Study: 335000
Drug: Whole-virus vaccine
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virus vaccine
Study: 7410896
Drug: Bivalent subvirion
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent subvirion vaccine
Study: 23208460
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 mg)
Study: 23208460
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 mg)
Study: 20609098
Drug: Intramuscular lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular lipid
Study: 18206407
Drug: Platelet-rich gel
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich gel (PRG) treatment
Study: 18206407
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no PRG treatment)
Study: 16339924
Drug: GnRH-receptor antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH-receptor antagonist (graded doses)
Study: 8614377
Drug: Study solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study solution (25 microgram/ml of both amikacin and vancomycin added to the standard solution)
Study: 8614377
Drug: Standard solution
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard solution (normal saline + 100 U/ml of heparin)
Study: 1475987
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral dose of famotidine administered at 10:00 p.m.
Study: 1475987
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral dose of famotidine administered at 6 p.m.
Study: 3900079
Drug: Ioxaglate 320
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate 320 mg/ml
Study: 3900079
Drug: Ioxaglate 200
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate 200 mg/ml